Fiji vs United States Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Fiji
0.2%
in 2024
United States Virgin Islands
0.2%
in 2024
Fiji rank
98th
United States Virgin Islands rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Fiji
- United States Virgin Islands
How they compare
Fiji currently reports 0.2% against 0.2% in United States Virgin Islands, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was United States Virgin Islands ahead.
Fiji ranks 98th and United States Virgin Islands ranks 98th of 246 countries.
Across the 2 decades both report, Fiji averaged higher in 1 and United States Virgin Islands in 1.
Head to head by decade
| Decade | Fiji | United States Virgin Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | United States Virgin Islands |
| 2020s | 0.3% | 0.2% | 0.1% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Fiji or United States Virgin Islands?
- Fiji, at 0.2% against 0.2% in United States Virgin Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Fiji and United States Virgin Islands?
- 0.0%, with Fiji ahead.
- How many years of comparable data are there for Fiji and United States Virgin Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Fiji and United States Virgin Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Fiji ranks 98th and United States Virgin Islands ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.